Marrone Bio Innovations (NASDAQ:MBII) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $9.86 million which missed the analyst consensus estimate of $10.63 million by 7.28 percent. This is a 11.64 percent increase over sales of $8.83 million the same period last year.
Stifel Maintains Buy on Masonite International, Raises Price Target to $98
Stifel analyst Stanley Elliott maintains Masonite International (NYSE:DOOR) with a Buy and raises the price target from $97 to $98.
